Undisclosed Trispecific T-cell Engager / Candid Therapeutics, WuXi AppTec - LARVOL DELTA

Candid Therapeutics Enters into Agreement with WuXi Biologics on Trispecific T-cell Engager (Businesswire) - "Candid Therapeutics..., a clinical-stage biotechnology company focused on becoming the leader in advancing T-cell engagers for autoimmune and inflammatory diseases, announced today an agreement with WuXi Biologics under which Candid will have exclusive global rights to a preclinical trispecific T-cell Engager discovered at WuXi Biologics’ proprietary universal multispecific antibody platform WuXiBody. Candid plans to complete IND enabling studies to enable first-in-human studies in the first half of 2026....Under the terms of the agreement, WuXi Biologics is entitled to obtain an upfront payment, and development and sales milestones totaling up to $925 million as well as royalties."

Licensing / partnership • New trial • Immunology • Inflammation